VOLITIONRX LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone 2018-01-03 21:30
VolitionRx Limited to Attend Conferences in December 2017-12-05 20:30
VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update 2017-11-10 05:05
VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update 2017-11-02 20:30
VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits 2017-09-22 20:30
VolitionRx Announces its European Colorectal Cancer Strategy 2017-09-20 04:30
VolitionRx to Attend Two Major Conferences in Asia 2017-09-15 19:30
Volition Granted Four Additional Patents 2017-09-14 20:00
VolitionRx Limited to Attend Multiple Conferences in September 2017-09-07 04:30
Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers 2017-08-23 04:30
VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update 2017-08-10 04:05
VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update 2017-08-04 04:30
VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute 2017-07-20 04:30
Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute 2017-07-18 18:30
Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress 2017-06-30 21:22
VolitionRx Limited Corrects an Earlier Announcement 2017-06-27 19:30
VolitionRx Limited to Present at Multiple Investor Conferences in June 2017-05-26 18:30
A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays 2017-05-18 21:00
VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update 2017-05-11 18:30
VolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate the Performance of its Nu.Q(TM) Triage Test 2017-05-09 19:30
1 4 5 6 7 8 11